drugset
drugset / Trial / NCT00485667

Phase 1 Thorough QT Study in Young Healthy Volunteers

NCT00485667 ↗

Phase 1 Completed 48 enrolled Pacira Pharmaceuticals, Inc Richmond Pharmacology Limited · collab
RandomizedCrossoverDouble-blindTreatment

Summary

A reduction in the postoperative need for opioids to enhance the recovery process and increase patient postoperative satisfaction.

Timeline

Start
2007-06
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupivacaine Other / unclassified 300 mg Subcutaneous
Subject Bupivacaine Other / unclassified 450 mg Subcutaneous
Subject Moxifloxacin Small molecule 400 mg —

Indications

No indication recorded.